To demonstrate that SUMO2 protects FASN against proteasomal degradation, we treated the breast cancer cell lines with a protein synthesis inhibitor (CHX) and a proteasomal degradation inhibitor (MG132) in combination with SUMO2 silencing. Here, SUMO2 is linked to breast cancer.